Merck, Celera Extend Osteoporosis Drug Discovery Deal | GenomeWeb

NEW YORK, Dec. 12 – Celera Genomics and Merck said Wednesday that they had agreed to extend their osteoporosis drug discovery deal for a sixth year.

This is the fourth extension for the research collaboration. The original deal dates back to November 1996 when Celera’s South San Francisco operations, then Axys Pharmaceuticals, penned a two-year drug discovery deal with Merck.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.